Rescue Pacing for Congenital Complete Heart Block

This project aims to develop a gene therapy using adenoviral vectors to increase heart rates in fetuses with congenital complete heart block, enabling safe pacemaker implantation post-birth.

Subsidie
€ 150.000
2022

Projectdetails

Introduction

Congenital heart block is the most commonly observed type of foetal bradycardia, occurring in one in 15,000 live births. A significant subset of foetuses develops towards congenital complete heart block (CCHB), i.e., complete failure of the electrical excitation wavefront to be conducted over the atrioventricular (AV) node.

Significance of CCHB

CCHB is the most severe and life-threatening cardiac arrhythmia in utero. Current medicinal treatments cannot significantly alter the cause of CCHB and therapeutic attempts at human foetal cardiac pacing have been unsuccessful.

Project Objective

For CCHB patients at high risk for life-threatening disease progression and death due to severe bradycardia before 34 weeks of gestation, this project develops a gene therapy medicinal product (GTMP) that is based on adenoviral vector-mediated ion channel overexpression.

Expected Outcomes

The goal is to transiently increase heart rates over the course of several months. When successful, such a GTMP would rescue these patients and allow for permanent pacemaker implantation in the first months after birth.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-8-2022
Einddatum31-1-2024
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • STICHTING AMSTERDAM UMCpenvoerder

Land(en)

Netherlands

Vergelijkbare projecten binnen European Research Council

ERC STG

MANUNKIND: Determinants and Dynamics of Collaborative Exploitation

This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.

€ 1.497.749
ERC STG

Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure

The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.

€ 1.498.280
ERC STG

Uncovering the mechanisms of action of an antiviral bacterium

This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.

€ 1.500.000
ERC STG

The Ethics of Loneliness and Sociability

This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.

€ 1.025.860

Vergelijkbare projecten uit andere regelingen

EIC Transition

Transcription Factor Gene Therapy for Bradyarrhythmias

PacingCure's TRACTION project aims to optimize and validate BradyTx-01, a gene therapy for cardiac pacing dysfunctions, ensuring safety, efficacy, and a pathway to commercialization.

€ 2.499.968
ERC STG

Reversible and irreversible cardiac electroporation: Establishing the fundamentals to advance cardiac treatments

This project aims to understand cardiac electroporation mechanisms to develop methods for effective irreversible and reversible treatments for atrial fibrillation and ischemic heart disease.

€ 1.500.000
EIC Pathfinder

Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic cardiomyopathy diagnosis and treatment

The project aims to integrate genomics, proteomics, and structural analyses to clarify genotype-phenotype relationships in arrhythmogenic cardiomyopathy, paving the way for novel therapies.

€ 3.740.868
EIC Pathfinder

NaV1.5 regulation fine-tuning as a therapy for cardiac Conduction and Arrhythmic diseases at Risk of suddEn Death

The NaV1.5-CARED consortium aims to develop innovative therapies for cardiac arrhythmias by identifying genetic factors and therapeutic targets to restore NaV1.5 function and personalize risk assessment.

€ 4.546.205